SCHEMBL21348780

SCHEMBL21348780

CCc1cccc(NC(=O)c2nnc(C)o2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.57
▸ MAPT P10636 4/20 0.57
▸ LMNA P02545 3/20 0.57
▸ THRB P10828 2/20 0.57
▸ TP53 P04637 1/20 0.57
▸ TAS1R3 Q7RTX0 1/20 0.54
▸ TAS1R1 Q7RTX1 1/20 0.54
▸ TAS1R2 Q8TE23 1/20 0.54
▸ RAB9A P51151 3/20 0.49
▸ NPC1 O15118 2/20 0.49
▸ POLB P06746 2/20 0.49
▸ AR P10275 1/20 0.49
▸ CBR1 P16152 1/20 0.49
▸ AKR1C3 P42330 1/20 0.49
▸ SMN1; SMN2 Q16637 4/20 0.47
▸ HDAC3 O15379 1/20 0.47
▸ HDAC4 P56524 1/20 0.47
▸ HDAC1 Q13547 1/20 0.47
▸ HDAC7 Q8WUI4 1/20 0.47
▸ HDAC2 Q92769 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21348773 0.83 KMT2A (0.56) ALDH1A1MAPTLMNATP53RAB9A
SCHEMBL21695764 0.80 CBLB (0.42) ALDH1A1MAPTTP53RAB9ANPC1
SCHEMBL18415349 0.80 MEN1 (0.51) ALDH1A1MAPTLMNARAB9ANPC1
SCHEMBL21695763 0.79 FADS1 (0.52) ALDH1A1TP53RAB9ANPC1AKR1C3
SCHEMBL4319038 0.76 MAPT (0.64) ALDH1A1MAPTLMNATP53TAS1R3
SCHEMBL9979193 0.75 ALDH1A1 (0.62) ALDH1A1MAPTLMNATHRBTP53
SCHEMBL21348466 0.75 SMN1; SMN2 (0.73) ALDH1A1MAPTLMNATHRBTP53
SCHEMBL7770821 0.75 HPGD (0.68) ALDH1A1MAPTLMNATP53TAS1R3
SCHEMBL8996654 0.73 MAPT (0.64) ALDH1A1MAPTLMNATP53TAS1R3
SCHEMBL12314962 0.73 KCNK9 (0.69) ALDH1A1MAPTRAB9ANPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10556898-B2 Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease LYCERA CORPORATION (US) 2020-02-11 — — US disclosed
US-20190276447-A1 INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE LYCERA CORPORATION 2019-09-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190276447-A1 INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE ROCK1, ROCK2, TNK2 ALDH1A1 3126/4885MAPT 1874/4885LMNA 3711/4885
US-10556898-B2 Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease ROCK1, ROCK2, TNK2 ALDH1A1 3126/4885MAPT 1874/4885LMNA 3711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback